Inflammatory Bowel Disease - Pipeline Review, H1 2014 is a new market research publication announced by Reportstack. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects.
The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
- The report provides a snapshot of the global therapeutic landscape of Inflammatory Bowel Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Inflammatory Bowel Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Boehringer Ingelheim GmbH Amgen Inc. Sanofi Athersys, Inc. GlaxoSmithKline plc Biotec Pharmacon ASA Emergent BioSolutions Inc. Takeda Pharmaceutical Company Limited BioLineRx, Ltd. TiGenix NV ASKA Pharmaceutical Co., Ltd. Eisai Co., Ltd. Mitsubishi Tanabe Pharma Corporation Ono Pharmaceutical Co., Ltd. Paratek Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. 4SC AG Addex Therapeutics AlbireoPharma iCo Therapeutics Inc. Basilea Pharmaceutica AG Compugen Ltd. Pluristem Therapeutics Inc. Galapagos NV Synta Pharmaceuticals Corp. Sareum Holdings plc Sucampo Pharmaceuticals, Inc. MetrioPharm AG Advinus Therapeutics Ltd. Affimed Therapeutics AG Axxam SpA ActogeniX NV Omni Bio Pharmaceutical Inc. Am-Pharma B.V. Jenrin Discovery, Inc. Upsher-Smith Laboratories, Inc. Ventria Bioscience Aquinox Pharmaceuticals Inc. Argos Therapeutics, Inc. Catabasis Pharmaceuticals, Inc. Opsona Therapeutics Ltd. Inotek Pharmaceuticals Corporation Zealand Pharma A/S Giuliani S.p.A. Vitae Pharmaceuticals, Inc. Kyorin Pharmaceutical Co., Ltd. Synergy Pharmaceuticals, Inc. Ensemble Discovery Corporation Celsus Therapeutics Plc Medestea Research & Production S.p.A. Antibe Therapeutics, Inc. Nephrx Corporation SunTen Phytotech Co., Ltd. Ferring Pharmaceuticals, Inc. Janssen Biotech, Inc. Protagonist Therapeutics Inc. Lycera Corp. Pepscan Therapeutics N30 Pharmaceuticals GlycoMar Limited RaQualia Pharma Inc. Atlantic Healthcare Limited Sigmoid Pharma Ltd. ProNoxis AB ProtAb Ltd Complix NV Amakem NV Delenex Therapeutics AG Creabilis SA SK Biopharmaceuticals Co., Ltd. ReveraGen BioPharma, Inc. ChironWells GmbH GT Biologics Limited
If you purchase this report, you can get free access to any one company profile and its SWOT analysis from 50,000 company profiles available at Reportstack.
To view the table of contents and know more details please visit Inflammatory Bowel Disease - Pipeline Review, H1 2014.